Requirements for global elimination of hepatitis B: a modelling study

2014 Stanaway, 2016, The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013, Lancet, 10.1016/S0140-6736(16)30579-7 2015, Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013, Lancet, 385, 117, 10.1016/S0140-6736(14)61682-2 Thio, 2015, Global elimination of mother-to-child transmission of hepatitis B: revisiting the current strategy, Lancet Infect Dis, 15, 981, 10.1016/S1473-3099(15)00158-9 Andersson, 2015, Mother-to-child transmission of hepatitis B virus in sub-Saharan Africa: time to act, Lancet Glob Health, 3, e358, 10.1016/S2214-109X(15)00056-X Peto, 2014, Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986–90) and in the nationwide immunisation program, BMC Infect Dis, 4, 7, 10.1186/1471-2334-14-7 Chen, 2012, Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV, Gastroenterology, 142, 773, 10.1053/j.gastro.2011.12.035 Zhang, 2014, Individualized management of pregnant women with high hepatitis B virus DNA levels, World J Gastroenterol, 20, 12056, 10.3748/wjg.v20.i34.12056 Liaw, 2004, Lamivudine for patients with chronic hepatitis B and advanced liver disease, N Engl J Med, 351, 1521, 10.1056/NEJMoa033364 Papatheodoridis, 2010, Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review, J Hepatol, 53, 348, 10.1016/j.jhep.2010.02.035 2014 2013 Ott, 2012, Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity, Vaccine, 30, 2212, 10.1016/j.vaccine.2011.12.116 Ott, 2012, The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions, BMC Infect Dis, 12, 131, 10.1186/1471-2334-12-131 Lok, 2007, Chronic hepatitis B, Hepatology, 45, 507, 10.1002/hep.21513 2009, EASL Clinical Practice Guidelines: management of chronic hepatitis B, J Hepatol, 50, 227, 10.1016/j.jhep.2008.10.001 2015 2008 2013 2014 Mackie, 2009, Hepatitis B immunization strategies: timing is everything, CMAJ, 180, 196, 10.1503/cmaj.081112 Beasley, 1983, Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine, Lancet, 2, 1099, 10.1016/S0140-6736(83)90624-4 Lee, 2006, Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis, BMJ, 332, 328, 10.1136/bmj.38719.435833.7C Xu, 1985, Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial, Pediatrics, 76, 713, 10.1542/peds.76.5.713 Beasley, 1977, The e antigen and vertical transmission of hepatitis B surface antigen, Am J Epidemiol, 105, 94, 10.1093/oxfordjournals.aje.a112370 Wong, 1984, Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study, Lancet, 1, 921, 10.1016/S0140-6736(84)92388-2 Schweitzer, 2015, Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013, Lancet, 386, 1546, 10.1016/S0140-6736(15)61412-X 2013 Xu, 2003, Household catastrophic health expenditure: a multicountry analysis, Lancet, 362, 111, 10.1016/S0140-6736(03)13861-5 Lu, 2013, Direct economic burden of hepatitis B virus related diseases: evidence from Shandong, China, BMC Health Serv Res, 13, 37, 10.1186/1472-6963-13-37 Piot, 2015, Defeating AIDS—advancing global health, Lancet, 386, 171, 10.1016/S0140-6736(15)60658-4 2014 Lemoine, 2016, Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study, Lancet Glob Health, 4, e559, 10.1016/S2214-109X(16)30130-9 Nayagam, 2016, Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis, Lancet Glob Health, 4, e568, 10.1016/S2214-109X(16)30101-2 Zeisel, 2015, Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure, Gut, 64, 1314, 10.1136/gutjnl-2014-308943 Goldstein, 2005, A mathematical model to estimate global hepatitis B disease burden and vaccination impact, Int J Epidemiol, 34, 1329, 10.1093/ije/dyi206 Edmunds, 1996, Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas, Epidemiol Infect, 117, 313, 10.1017/S0950268800001497 Williams, 1996, The transmission dynamics of hepatitis B in the UK: a mathematical model for evaluating costs and effectiveness of immunization programmes, Epidemiol Infect, 116, 71, 10.1017/S0950268800058970 Kretzschmar, 2009, Model based analysis of hepatitis B vaccination strategies in the Netherlands, Vaccine, 27, 1254, 10.1016/j.vaccine.2008.12.009 Parkin, 2006, The evolution of the population-based cancer registry, Nat Rev Cancer, 6, 603, 10.1038/nrc1948 Shimakawa, 2014, The association between maternal hepatitis B e antigen status, as a proxy for perinatal transmission, and the risk of hepatitis B e antigenaemia in Gambian children, BMC Public Health, 14, 532, 10.1186/1471-2458-14-532